81512
document
A controlled trial of cisapride in anorexia nervosa . To determine the efficacy of cisapride , 10 mg three times daily , in improving gastric emptying , reducing distress during meals , and facilitating weight gain in anorexia nervosa , we conducted an 8-week , randomized , double-blind , placebo-controlled trial on 29 inpatients . Measures included scintigraphic gastric emptying studies at 0 , 2 , 4 , and 8 weeks ; subjective distress during meals measured by visual analogue scales ; self-rating of degree of global improvement in symptoms associated with eating at end of study ; and weight measured weekly . Gastric emptying improved significantly but equally in both groups over the study period . Yet subjective measures were better in the cisapride group ; they rated themselves as more hungry ( p = .02 ) and more improved on the global measure of change in symptoms ( p = .02 ) . Even so , the cisapride group did not gain more weight . The correlation between gastric emptying and weight gain was modest ( r = .30 ; p = .11 ) , and between gastric emptying and the subjective measures , virtually absent .
81513
Intervention_Pharmacological
cisapride
81514
Intervention_Pharmacological
cisapride
81515
Intervention_Control
placebo-controlled
81516
Intervention_Pharmacological
cisapride
81517
Outcome_Other
efficacy
81518
Outcome_Physical
gastric emptying
81519
Outcome_Mental
distress during meals
81520
Outcome_Mental
weight gain
81521
Outcome_Mental
subjective distress during meals
81522
Outcome_Other
visual analogue scales
81523
Outcome_Other
self-rating of degree of global improvement in symptoms associated with eating
81524
Outcome_Mental
weight
81525
Outcome_Physical
Gastric emptying
81526
Outcome_Mental
hungry
81527
Outcome_Other
change in symptoms
81528
Outcome_Mental
weight
81529
Outcome_Physical
gastric emptying
81530
Outcome_Mental
weight gain
81531
Outcome_Physical
gastric emptying
81532
Participant_Condition
anorexia nervosa
81533
Participant_Condition
anorexia nervosa
81534
Participant_Sample-size
29
81535
Participant_Condition
both
81536
Participant_Condition
cisapride
81537
Participant_Condition
cisapride